BTLA and neoplasm: The trial helps to answer the following questions: first, whether neoadjuvant therapy with BTLA inhibitors in combination with PD-l and chemotherapy (TP regimen) better improves tumor downstaging and achieves higher pCR rates; second, whether IO-IO immunotherapy results in more associated immune adverse effects; and third, whether BTLA inhibitors and PD-l adjuvant therapy provide non-CR and pCR patients with additional dual survival benefit.